First-in-U.S. blood test that assesses risk of heart attack using plasma ceramides

A new type of blood test has been launched that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease (CAD). The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.